GlassScriptPhysician profile
Mohammed A Ali
NPI 1962476143
$48,616.34
in general payments reported to CMS, 2019-2025
28 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,577 · 2020: $387 · 2021: $21K · 2022: $5,292 · 2023: $12K · 2024: $947 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $2,296 · Travel and Lodging: $901 · Royalty Or License: $225 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,200.00 |
| Food and Beverage | $2,295.85 |
| Travel and Lodging | $901.28 |
| Royalty Or License | $225.00 |
| Education | $158.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meridian Bioscience INC. | $21,850.50 | 2019-2024 | |
| Medtronic, INC. | $21,542.27 | 2021-2022 | |
| Abbvie INC. | $1,522.52 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Roche Diagnostics Corporation | $901.28 | 2023 | Iscan Coreo, Virtuoso System For Ihc |
| Celgene Corporation | $519.14 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $425.46 | 2019-2023 | Stelara |
| Pfizer INC. | $345.01 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $252.50 | 2021-2023 | |
| Genzyme Corporation | $202.01 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.63 | 2019-2025 | Entyvio |
| Conmed Corporation | $150.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.91 | 2019-2024 | Xifaxan |
| Boston Scientific Corporation | $115.43 | 2022 | |
| Ardelyx, INC. | $59.92 | 2025 | Ibsrela |
| Celltrion USA INC. | $59.50 | 2024 | Zymfentra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $52.46 | 2019 | |
| Daiichi Sankyo INC. | $47.61 | 2019-2022 | |
| Braintree Laboratories, INC. | $41.19 | 2019 | |
| Ferring Pharmaceuticals INC. | $39.59 | 2022-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $23.26 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.50 | 2024 | Cyltezo |
| Novo Nordisk INC | $19.97 | 2025 | Wegovy |
| Kyowa Kirin, INC. | $17.57 | 2019 | |
| Aimmune Therapeutics, INC. | $17.23 | 2025 | Zenpep |
| Exact Sciences Corporation | $15.37 | 2025 | Cologuard Collection Kit |
| Endogastric Solutions, INC | $15.14 | 2024 | Esophyx |
| Merck Sharp & Dohme LLC | $11.29 | 2019 | |
| Qol Medical, LLC | $7.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.